All News

Despite common trends in the specialty drug market persisting, a new pharmacy landscape must come together to address rising issues.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.

ECO 2026 data shows Wegovy cuts migraines, depression, and heart risk in menopausal women, as glucagon-like peptide-1s' demand challenges pharmacists.

Opioid pain care shifts fast, and pharmacists and pharmacies lead safer prescribing, naloxone education, and monitoring to curb overdose deaths.

Researchers explore invasive pneumococcal disease epidemiology after the introduction of multiple pneumococcal conjugate vaccines.

New research shows inflammation and diabetes raise preterm birth risk, suggesting C-reactive protein testing.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

As artificial intelligence becomes commonplace in medical practice, officials are gradually uncovering significant safety risks.

By late February 2026, national data from the CDC reveal a test positivity rate of 9.1%, the highest recorded for the entire season at that point.

In part 2, Kevin Day, PharmD, breaks down the Pharmacy Quality Rewards Program and its push toward value-based care in pharmacy practice.

As accessible and trusted health care providers, pharmacists have important roles to play in helping patients mitigate the impact of heat on their health.

Exploring clinical prioritization and macroeconomic investment, researchers examine the link between disease and economic burden of diabetes.

GLP-1 prescriptions surge to nearly 8% of fills, fueled by weight-loss demand.

With continued pressure for federal action regarding the abortion drug mifepristone, SCOTUS blocked a previous decision that would limit the pill’s access.

FDA clears Langlara interchangeable insulin glargine, enabling pharmacy substitution for Lantus and widening affordable basal insulin access.

Despite WHO officials stating that risks from the outbreak remain low, experts are acting urgently to uncover details and provide support.

The FDA expands Auvelity for Alzheimer-related agitation, offering a first nonantipsychotic option backed by trials.

Utilizing colleges and schools of pharmacy, researchers explorensolutions to the growing challenges affecting community pharmacy.

Among community pharmacies and their patients, researchers explore the power of protected learning time for improving services and outcomes.

With its capabilities improving rapidly in the health care space, technology and pharmacy experts discuss AI’s future place in pharmacy practice as further developments are released.

These discussions focused on gaps in artificial intelligence, community-based advanced therapy, and demands of federal drug price negotiations.

An exploration of community pharmacists’ perceptions of e-pharmacy, assessing whether they believe it’s a threat or benefit.

FDA approves Caplyta to prevent schizophrenia relapse, cutting risk 63% with a stable metabolic profile.

Digital specialty pharmacy, AI-driven intent, and mega-blockbuster drugs reshape patient engagement, access, and long-term adherence strategies.

In adult patients at least 50 years old, researchers estimated lifetime costs and health outcomes of the 23-valent pneumococcal polysaccharide vaccine.

In part 2 of our World Immunization Week interview with Nathan Ott, PharmD, he discusses the power of collaboration and continuing education in boosting vaccine awareness.

Pharmacy benefit manager reforms, gene therapy scale-up, artificial trust risks, and more reshape specialty pharmacy.

The adeno-associated virus (AAV) vector-based gene therapy lunsotogene parvec-cwha received approval through the FDA Commissioner’s National Priority Voucher pilot program.